Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Amir, Kalali"'
Autor:
Amir Kalali
Publikováno v:
Alzheimer's & Dementia. 18
Autor:
Masoudreza, Sohrabi, Ali, Gholami, Bahareh, Amir Kalali, Mahmoodreza, Khoonsari, Roghieh, Sahraei, Mohsen, Nasiri Toosi, Farhad, Zamani, Hossein, Keyvani
Publikováno v:
Middle East Journal of Digestive Diseases. 13:356-362
BACKGROUND Inflammation has a significant impact on the development and progression of fatty liver diseases.In this study, we aimed to investigate the relation between serum levels of nuclear factor kappa B (NFkB) and Forkhead box protein P3 (FOXP3)w
Publikováno v:
Journal of Alzheimer's disease : JAD. 87(1)
Given the acknowledged lack of success in Alzheimer’s disease (AD) drug development over the past two decades, the objective of this review was to derive key insights from the myriad failures to inform future drug development. A systematic and exha
Autor:
Amir, Kalali
Publikováno v:
Innov Clin Neurosci
Autor:
David, Daniel, Amir, Kalali, Mark, West, David, Walling, Dana, Hilt, Nina, Engelhardt, Larry, Alphs, Antony, Loebel, Kim, Vanover, Sarah, Atkinson, Mark, Opler, Gary, Sachs, Kari, Nations, Chris, Brady
Publikováno v:
Innovations in clinical neuroscience. 13(1-2)
This paper summarizes the results of the CNS Summit Data Quality Monitoring Workgroup analysis of current data quality monitoring techniques used in central nervous system (CNS) clinical trials. Based on audience polls conducted at the CNS Summit 201
Autor:
Teruhiko Higuchi, Hiroshi Naitoh, Norio Ozaki, Nakao Iwata, Amir Kalali, Tatsuo Akechi, Kunihiko Shioe, Hideaki Tabuse, Hideki Azuma, Toshi A. Furukawa, Shigenobu Kanba
Publikováno v:
Psychiatry Research. 153:61-67
The Hamilton Rating Scale for Depression (HAMD) is the de facto international gold standard for the assessment of depression. There are some criticisms, however, especially with regard to its inter-rater reliability, due to the lack of standardized q
Publikováno v:
Innovations in clinical neuroscience. 11(11-12)
There is currently no accepted standard for the clinical research industry to follow when selecting and training raters to administer rating scales in clinical neuroscience trials. This article offers guidelines, based on expert recommendations of th
Autor:
Ricardo F. Allegri, H. Michael Arrighi, Pablo M. Bagnati, Menghis Bairu, Sonia Brucki, Tal Burt, Lorne Cheeseman, Richard Chin, Debbie N. Cote, Jeffrey Cummings, Stephanie Danandjaja, P. Murali Doraiswamy, Murat Emre, James (Dachao) Fan, Yoko Fujimoto, Michel Grothe, Ibrahim Hakan Gürvit, Spencer Guthrie, Harald Hampel, Lynne Hughes, Michael Hüll, Hilal İlbars, Takeshi Iwatsubo, Roy W. Jones, Nadina C. Jose, Amir Kalali, Seong Yoon Kim, Miia Kivipelto, Bernd J. Krause, Jens Kurth, Huafang Li, Francesca Mangialasche, Hans J. Möbius, Ricardo Nitrini, Tiia Ngandu, Muriel O’Byrne, Peter Schüler, Klaudius Siegfried, Sidney A. Spector, Stefan Teipel, Yağiz Üresin, Michael Weiner, Jing Yin, Xue (Kate) Zhong
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0ddf95cb08be205d45de9a3c12a30420
https://doi.org/10.1016/b978-0-12-411464-7.00027-4
https://doi.org/10.1016/b978-0-12-411464-7.00027-4
Central Nervous System disorders have an enormous impact on individuals and on society as a whole. The development of better treatments is crucial and is a major focus of pharmaceutical and biotechnology companies. This book explains the complicated